Read the small print
Can a pharmacy make BPC-157 for me?
Start with the answer for ordinary pharmacy preparation from raw ingredients, then read why a prescription and an advisory meeting do not settle the rules.
FDA—the Food and Drug Administration—handles US reviews of medicines.
With compounding, a patient’s particular need shapes the medicine a doctor or pharmacist prepares to order.
The federal ingredient rules checked on 26 September 2026 did not permit ordinary pharmacies to prepare a patient’s BPC-157 medicine using raw ingredients.
- Drug approval
On 28 September 2026, BPC-157 had no approved US medicine for any use.
No country had an approved medicine containing BPC-157, according to the FDA’s review.
- A request taken back
On the FDA page dated 22 April 2026, the groups that asked to let pharmacies use BPC-157 had taken their requests back. The FDA still prints its safety concerns.
The page lists it under requests taken back, rather than Category 2, the group of ingredients flagged for significant safety concerns.
Taking back those requests did not approve BPC-157 or give pharmacies permission to make it to order.
Does a prescription settle the rules?
The federal route for ordinary pharmacy compounding requires a prescription for a named patient, as checked on 26 September 2026.
If the ingredient has written quality requirements in the medicine reference books named in the law, the pharmacy must follow them.
If those books have no requirements for it, there are two other ways to meet the ingredient rules. The ingredient must appear on the FDA’s list for this kind of pharmacy preparation, or be part of a medicine the FDA has approved.
BPC-157 did not meet any of these legal requirements for ingredients at the 26 September 2026 review. These are rules about what pharmacies may use, not laboratory tests.
In July 2026, FDA reviewers examined two versions of the ingredient itself: BPC-157 acetate and the form named BPC-157 (free base). Neither had written quality requirements in those books, and neither was in an approved medicine.
Neither ingredient was on the FDA’s list of other ingredients allowed for this kind of pharmacy preparation, and FDA staff proposed keeping both off it.
Ask: “Which law allows the pharmacy to make this exact ingredient into a medicine for me? Please give me the rule and explain in writing how this medicine meets it.” A prescription alone does not answer that question.
What happened at the advisory meeting?
The advisory meeting took place on 23 and 24 July 2026, but the 28 September 2026 check found no FDA record of its votes.
The committee advises the FDA. To change the list of ingredients pharmacies may use, the FDA must publish a proposed rule, invite public comments and publish a final rule.
If an offer says the rules changed after a meeting, ask to see the FDA’s final rule and where it names this ingredient.